Dimerix Limited · ASX:DXB
Dimerix — 18th Bioshares Biotech Summit 2024
24 slides from Dimerix's conference presentation, Jul 12, 2024
Slide 1: Dimerix presents at Bioshares Biotech Summit
Immediate Release DIMERIX PRESENTS AT BIOSHARES BIOTECH SUMMIT MELBOURNE, Australia, 12 July 2024: Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in inflammatory disease, is pleased to advise that CEO and Managing Director, Dr Nina Webster, will be presenting a
Slide 2: About FSGS Phase 3 Study, Dimerix and DMX 200
About FSGS Phase 3 Study The Phase 3 study, which is titled “Angiotensin II Type 1 Receptor (AT1R) & Chemokine Receptor 2 (CCR2) Targets for Inflammatory Nephrosis”, or ACTION3 for short, is a pivotal (Phase 3), multi-centre, randomised, double-blind, placebo-controlled study of the efficacy and saf
Slide 3: Orphan Drug Designation and references
cases diagnosed in the US alone each year. 4 Because there is no effective treatment, Dimerix has received Orphan Drug Designation for DMX 200 in both the US and Europe for FSGS. Orphan Drug Designation is granted to support the development of products for rare diseases and qualifies Dimerix for var
Slide 4: What's the big deal? Inside a licensing deal
(ASX:DXB) What's the big deal? gin nside a licensing deal ioshares Summit uly 2024 LL Developing new therapies to treat inflammatory causes of kidney and respiratory disease with unmet clinical needs ACTIONS FSGS CLINICAL STUDY Authorised for lodgement by the Board of the Company
Slide 5: Conference theme: Finding the Next Blockbuster Drug
Conference theme: Finding the Next Blockbuster Drug discuss the approach to achieving this goal, including partnering and clinical trial data a © Questions posed to Dimerix: je) © 1. Two license deals: how long did these deals take to conclude, what were the main points to negotiate, how Yn ° much d
Slide 6: Dimerix - in context
ACTIGNS FSGS CLINICAL STUDY DIMERIX - IN CONTEXT For personal use only @ Dimerix
Slide 7: Lead drug candidate, FSGS indication, validation
Lead Drug Candidate For personal use only • • FSGS Indication • • • Commercial and Technical Validation •
Slide 8: Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis (FSGS) How do you measure kidney function? * Historically, measured using “hard” endpoints for kidney disease < Focal = some . kidney failure) -which may not be reached for decades! ° Segmental = sections ! y y y . . . * Regulatory agencies and national bodies now
Slide 9: Why are kidneys important? Why is proteinuria important?
Why are kidneys important? Why is proteinuria important? For personal use only
Slide 10: Primary endpoint: eGFR (kidney function) - example
Primary endpoint: eGFR (kidney function) - example Natural aging kidney function slope! * Kidney function can be measured using estimated glomerular filtration rate (eGFR): nly fo) o how many millilitres of blood is filtered by the ai’ kidney per minute per year 2 * eGFR slope naturally declines as
Slide 11: DMX-200: Phase 2 met primary and secondary endpoints
DMX-200: Phase 2 met primary and secondary endpoints a6 17% average reduction of proteinuria in Phase 2 is clinically meaningful! “reductions “10% in proteinuria translated to clinically meaningful differences in eGFR” Kidney survival study — Troost et al., August 2020! Da Adjusted models Cc - — - f
Slide 12: Background Phase 3 Trial Timeline
For personal use only Background Phase 3 Trial Timeline • • •
Slide 13: What are the trends in licensing therapeutics?
ACTIGNS FSGS CLINICAL STUDY WHAT ARE THE TRENDS IN LICENSING THERAPEUTICS? For personal use only @ Dimerix
Slide 14: Global partnering trends - Q1 2024
Global partnering trends — Q1 2024 The total number of deals across the sectors is R&D Partnerships — Global Healthcare and Life Sciences’ declining? ec Deal Value ($B) mam Total Upfront Cash and Equity ($B) ®=Number of Deals oan . 2023 and Ql 2024 $73.0 dealmaking environment oe De. we” oe 300 show
Slide 15: Kidney disease is high interest area for pharma
Kidney disease is high interest area for pharma Prevalence of Kidney Failure, 2001-20232 = Kidney disease is the third-fastest-growing ”, cause of death globally! In the US alone, the number of people with kidney failure increased by >200% from 2001 to 20232 By 2040, it is expected to become the fif
Slide 16: Dimerix - in deal making mode
ACTIGNS FSGS CLINICAL STUDY For personal use only DIMERIX - INDEAL MAKING MODE @ Dimerix
Slide 17: Summary of DMX-200 licensing deals
Summary of DMX-200 licensing deals Dimerix has validated the technology! and proven its ability to licence multiple territories, with more deals anticipated Summary ADVANZ & PHARMA pear) Other Licensing Deals (incl. US & China) For personal use sales Escalating mid-teen-20% EEA, Canada, Switzerland,
Slide 18: Getting our ducks in a row
| use only -Or persona GETTING OUR DUCKS IN A ROW al @ Dimerix
Slide 19: Preparation behind the scenes for partnering
• Container closure, shelf-life & product presentation For personal use only Global regulatory Commercial manufacturing, • pathways/minutes quality, Cost of Goods & supply chain Product development Competitive landscape, (pre-clinical/ epidemiology & market research clinical data) Many years behind
Slide 20: DMX-200 Business Development Plan
Dimer \ o Dimerix ov Dimerix DMx-200 | ent Plan pusiness Development P ersonatuse- only | Eor Potential partners identified as part of business development plan All materials are ready at the start of a partnering exercise xX partnering executed to plan ommunicatio! Materials Product Information Mar
Slide 21: Time to deal - actual timeline experience
Time to deal — actual timeline experience The time from first meeting to executing a license agreement takes time - it can take up to 2 years St is allin the planning and experience in doing deals: Dimerix has a number of parties — . i 1 C° Structure, tactics & outreach Cngeiet] elon ils [MerwES oF
Slide 22: Order of deals was strategic
Order of deals was strategic Commercial Validation Negotiation Leverage y, Further deals anticipated before Part 2 analysis; Dimerix negotiation Potential Marketing Part 2 analysis 1 1st deal — EU selected: anticipated mid-20252 commercially validate asset and prove partnering capabilities © before
Slide 23: Lead drug candidate, market opportunity, upcoming milestones
Lead Drug Candidate • For personal use only • FSGS Indication • • • Market Opportunity • • • o Commercial Validation • • Upcoming FSGS Milestones • •
Slide 24: Corporate overview
Corporate overview For personal use only Ticker Symbol ASX: DXB Cash Balance (Mar24) “A$35.2 million Market Capitalisation “A$250 million Share price ~A$0.46 Total ordinary shares on issue 550,211,758 Average Daily Liquidity by volume’ “51 million SHARE PRICE 07 50 Volumen) —shore Peed Cose Close pr